Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SH U 555 A)

Reimer, Peter; Allkemper, Thomas; Matuszewski, Lars; Balzer, Thomas

doi:10.1002/(sici)1522-2586(199907)10:1<65::aid-jmri9>3.0.co;2-0

Cited by 21 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, this subfraction contributes to the signal change on T1-weighted images and is the reason why the signal characteristics are comparable to those of angiographic agents with a blood-pool effect. This subfraction also explains the biexponential blood half-life of ferucarbotran, which has also been tested for its capability in contrast-enhanced MRA [23] . Enhancement increased with the degree of T1-weighting and shifted towards higher concentrations with shorter echo times.…”

Section: Discussionsupporting

confidence: 83%

FerucarbotranversusGd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions

Cheng

Zeng²,

Yan³

et al. 2007

WJG

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

FerucarbotranversusGd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions

Cheng

Zeng²,

Yan³

et al. 2007

WJG

View full text Add to dashboard Cite

“…First, the use of SPIO particles of AAAs. Our study confi rmed published in vivo and ex vivo data in which SPIO particles were successfully used to monitor phagocytic activities in nonaneurismal atherosclerotic plaques ( 16,(19)(20)(21)(22)(23). It has been shown that the specifi c pathophysiologic processes in AAA thrombi include leukocyte retention ( 24 ), matrix destruction ( 25 ), and proteolytic activities ( 10 ).…”

Section: Discussionmentioning

confidence: 99%

MR Imaging of Iron Phagocytosis in Intraluminal Thrombi of Abdominal Aortic Aneurysms in Humans

Nchimi¹,

Defawe²,

Brisbois³

et al. 2010

Radiology

View full text Add to dashboard Cite

show abstract

“…hypervascular hepatocellular lesions may demonstrate an initial signal increase [2,39]. MR angiography of the liver artery and portal venous system can be performed with these agents during the accumulation phase (when SPIO particles are being trapped by phagocytes in the organs), showing increased vascular signal by a suppression of background liver signal [40].…”

Section: Liver and Spleen Imagingmentioning

confidence: 97%

Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

2001

View full text Add to dashboard Cite

Superparamagnetic iron oxide MR imaging contrast agents have been the subjects of extensive research over the past decade. The iron oxide particle size of these contrast agents varies widely, and influences their physicochemical and pharmacokinetic properties, and thus clinical application. Superparamagnetic agents enhance both T1 and T2/T2* relaxation. In most situations it is their significant capacity to reduce the T2/T2* relaxation time to be utilized. The T1 relaxivity can be improved (and the T2/T2* effect can be reduced) using small particles and T1-weighted imaging sequences. Large iron oxide particles are used for bowel contrast [AMI-121 (i.e. Lumirem and Gastromark) and OMP (i.e. Abdoscan), mean diameter no less than 300 nm] and liver/spleen imaging [AMI-25 (i.e. Endorem and Feridex IV, diameter 80-150 nm); SHU 555A (i.e. Resovist, mean diameter 60 nm)]. Smaller iron oxide particles are selected for lymph node imaging [AMI-227 (i.e. Sinerem and Combidex, diameter 20-40 nm)], bone marrow imaging (AMI-227), perfusion imaging [NC100150 (i.e. Clariscan, mean diameter 20 nm)] and MR angiography (NC100150). Even smaller monocrystalline iron oxide nanoparticles are under research for receptor-directed MR imaging and magnetically labeled cell probe MR imaging. Iron oxide particles for bowel contrast are coated with insoluble material, and all iron oxide particles for intravenous injection are biodegradable. Superparamagnetic agents open up an important field for research in MR imaging.

show abstract

Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SH U 555 A)

Cited by 21 publications

References 28 publications

FerucarbotranversusGd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions

FerucarbotranversusGd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions

MR Imaging of Iron Phagocytosis in Intraluminal Thrombi of Abdominal Aortic Aneurysms in Humans

Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

Contact Info

Product

Resources

About